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Regression of Metastatic Osteosarcoma Following
Non-Myeloablative Stem Cell Transplantation.
A Case Report
We report the evidence of regression of multiple
metastases following non-myeloablative stem cell
transplantation (NST) from an HLA-identical sib-
ling in a case of relapsed fibroblastic osteosarco-
ma. The course of NST was well tolerated. Full
donor chimerism was achieved on day +150 both
for CD15+ and CD3+ cells. Complete remission
was achieved on day +116. On day +210 the
patient relapsed with a scapular metastasis that
was unresponsive to four doses of donor lympho-
cyte infusion (DLIs).To our knowledge, this is the
first reported case showing the achievement of
complete remission following NST in an osteosar-
coma patient.Haematologica 2007; 88:(5)e64-e66
Introduction.
Relapsed osteosarcoma with multiple bone metastases
is generally considered incurable using conventional
treatment.1 High dose chemotherapy and autologous
stem cell transplantation (ASCT) have improved the
remission rate but convincing evidence of disease free
survival (DFS)2 has never been shown. Progress in the
understanding of the immune response to cancer togeth-
er with an increased understanding of the basic mecha-
nism of cellular immunology have combined to open
new opportunities for the development of effective
immunotherapies for cancer.Patients with leukaemia
undergoing allogeneic stem cell transplantation (SCT)
and developing acute and, especially chronic GvHD run
a lower risk of relapse than those without GvHD.3
Furthermore, T cell depletion of the graft increases the
risk of relapse. Recent reports suggest that donor lym-
phocytes, transferred with the graft, may also produce a
clinically meaningful graft versus tumour (GvT) effect in
patients with refractory solid tumours, such as renal cell
carcinoma,4 breast cancer,5 colonic cancer,6 non-small cell
lung cancer,7 ovarian cancer8 and Ewing sarcoma.9 Based
on these data, attempts have been made to diminish
transplant related mortality and, possibly, morbidity
associated with conventional myeloablative allogeneic
stem cell transplantation. Recently, attention has been
addressed to less cytotoxic conditioning regimens to
obtain a mixed chimerism over which allogeneic cells
might display an anti-tumour effect.In this report, we
describe the evidence of the regression of multiple
metastases following non-myeloablative transplantation
(NST) in a case of relapsed fibroblastic osteosarcoma.
Patient and Donor.
In February 1997 a 12 year-old boy was diagnosed a
grade IV fibroblastic osteosarcoma of the right distal
femur. No metastasis was found at diagnosis. He
received neo-adjuvant chemotherapy according to the
ISG-SSG1 protocol (an Italian-Scandinavian chemothera-
py and surgery protocol) including high dose
Methotrexate, high dose Ifosfamide, Adriamycin and
Cis-platinum. In June 1997 he underwent resection of
the distal femur and insertion of a Kotz prothesis. The
histological examination showed 100% of tumour
necrosis. The patient finished post-surgery chemothera-
py in October 1997. The Adriamycin, Methotrexate,
Cisplatinum and Ifosfamide total doses administrated
were 330 mg/m2, 48 g/m2, 480 mg/m2 and 60 g/m2,
respectively. In October 2000 the patient underwent left
lung metastasectomy (+ 44 months from diagnosis). In
June 2001 (+ 52 months from diagnosis) the total body
scan with 99Tc showed multiple osseous metastases. A
CT scan showed a retro-orbital mass, whereas the lungs
were negative (Tab 1).10 Neoplastic cells were also found
in the bone marrow biopsy.The patient underwent a
modified ISG-AIEOP (Italian Sarcoma Group-Italian
Association of Paediatric Haematology Oncology) for
very high risk osteosarcoma patients, that was approved
by the Hospital Ethical Committee. The patient was
treated with three cycles of high dose Methotrexate
cycles (12 g/m2), a Cisplatinum-Adriamycin cycle (120
mg/m2 and 75 mg/m2, respectively) and a Cis-platinum
cycle (120 mg/m2). In November 2001 the total body
scan with 99Tc-Osteosol showed the partial uptake
reduction, while the retro-orbital cavity CT scan was
unchanged. As he had several healthy siblings, his 22-
year-old HLA-identical brother was chosen as a stem cell
donor.
Allogeneic stem cell transplantation. The patient received
Fludarabine 30 mg/m2/day over four days and
Cyclophosphamyde 30 mg/Kg/day over two days. The
graft versus host disease (GvHD) prophylaxis was:
Cyclosporin-A (Cy-A) 3 mg/Kg i.v. from day -1 to +84 to
maintain blood values between 100-250 ng/ml and
Mycofenolate Mofetil (MMF) 15 mg/Kg b.d. orally from
day 0 to +28. Cy-A tapering was started from day +84
until day +180 (7% weekly). Acyclovir was given for
viral prophylaxis 500 mg/m2 three times a day from day
&endash;5 and liposomal anphotericin 1 mg/Kg was
given for antifungal prophylaxis from day -1. For
Pneumocystis carinii prophylaxis aerosolized pentami-
dine 300 mg and, thereafter, trimethoprim-sulfametoxa-
zole 5 mg/Kg over two consecutive days each week was
given.The graft was: nucleated cells 10x108/Kg, CD34+
13.8x106/Kg, CFU-GM 60x104/Kg, CD3+ 2.22x108/Kg,
CD3+CD4+ 1.04x108/Kg, CD3+CD8+ 1.02x108/Kg,
CD19+ 2.8x107/Kg, CD56+ 3.2x107/Kg.
Immune reconstitution following. NST. Monthly, peripher-
al blood samples were analysed for CD3+, CD4+, CD8+,
CD19+ and CD56+ lymphocyte reconstitution. Cells
were analysed on a Becton Dickinson Facscan cytometer.
Molecular studies to monitor chimerism. DNA from patient
Table 1.
and donor pre-transplant samples was obtained using a
standard protocol. (Qiagen, Hilden, Germany). The sep-
aration of CD3+ and CD15+ cells from peripheral blood
was performed with immunomagnetic beads (Miltenyi
Biotec srl, Italy). Before freezing, 30 mM Tris buffer was
added to each cell pellet. After thawing, 60 µL of lysis
buffer was added to each bead-selected cell sample.
These samples were then digested at 37°C overnight on
a shaker, and subsequently diluted, as previously
described elsewhere. The cell lysate samples were heat-
ed to 70°C, then spun and cooled on ice. Polymerase
chain reaction (PCR) amplification of two different vari-
able number tandem repeats (VNTRs) were chosen for
mixed chimerism analysis.
Evaluation of tumour regression. Table 1 shows the
results of the re-staging performed periodically after
transplantation.
Results.
Transplant related toxicity. The patient did not develop
acute and chronic GvHD. Transplant related toxicity was
0 according to the Bearman score.
Haemopoietic engraftment. The patient achieved neu-
trophil engraftment (>500/µL) on day +14. The lower
platelet count was 119.000/µL. One packed red cell
transfusion was performed on day +1 (before transfusion
Hgb level 8.1 g/dL).
Immune reconstitution following NST. The CD4+ cell
reconstitution was monitored from day +27, however
since day+16 the total lymphocytes were >500/µL. As
reported in Table 2, also the CD19+ population showed
a quick recovery following NST.
Chimerism analysis. The PCR study for the VNTRs
showed from day+18 >50% of recipient cells in the bone
marrow. On day +37 the peripheral blood analysis for
mixed chimerism showed CD15+ and CD3+ cells with
>60% of donor origin and on day +84 the unseparated
bone marrow cells, the peripheral blood CD15+ and
CD3+ cells showed >70% of donor origin. On day +150
the patient achieved full donor chimerism. No evidence
of rejection emerged, even at the time of relapse.
Tumour response. On day +116 the head CT scan
showed complete remission of the retro-orbital mass,
and the total body scan with 99Tc-Osteosol showed no
active metastases. The complete remission status was
maintained until day +180. On day +210 following NST,
the patient relapsed with a single right scapular metasta-
sis. He received four, monthly, escalating doses of donor
lymphocyte infusion (DLIs): 1x107/Kg, 5x107/Kg,
7x107/Kg, 1x108/Kg CD3+ lymphocytes. No tumour
response or GvHD developed. The patient is now alive
with progressive disease on day +420 following trans-
plantation.
Discussion.
Patients with osteosarcoma and multiple bone metas-
tases have been shown to have a DFS of 0% at 4 years
follow-up 1. In a recently reported series, for patients
with early relapse, high dose chemotherapy with stem
cell rescue and pre or post-surgery, had a high remission
rate, but DFS remained low (12%) at 3 year follow-up 2.
Here, we report the evidence of metastases regression in
a patient with advanced osteosarcoma, in which the
immunological anti-osteosarcoma effect was independ-
ent of the GvHD reaction. Evidence that regression of
metastatic osteosarcoma cells was mediated by the graft
versus tumour (GvT) effect is compelling. First, the
Fludarabine and Cyclophosphamide preparative regimen
was administrated at immunosoppressive dosages, to
allow the donor’s immune cell engraftment, while avoid-
ing the substantial side-effects of myeloablative therapy.
Indeed, the conditioning regimen did not affect the
tumour growth as shown by the re-staging done on day
+30. Secondly, the regression of metastatic sites was
delayed as complete remission was not achieved before
day +116 following NST. Thirdly, the anti-tumour
response developed only after a mixed chimerism status
was obtained. A greater immunological difference
between donor lymphocytes and recipient tumour cells
may be the reason why allogeneic cells have an unequiv-
ocal anti-osteosarcoma effect in the NST setting in the
absence of any signs of GvHD. This phenomenon might
be explained considering that initially a mixed chimera is
formed, and the recipient and host T and B lymphocyte
and dendritic cells locate the thymus and delete host and
donor reactive T cells. This may result in a tolerant T cell
repertoire for both host and donor cells. Thus, the
formed mixed-chimera serves as a platform for adoptive
immunotherapy in which the risk for GvHD is reduced
as the severity of its clinical manifestation is also related
to the conditioning regimen and subsequent cytokine
release. The GvT effect is maintained by the host antigen
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presenting cell, which elicits the overall GvT effect by
recognising neoplastic antigens to donor lymphocytes.
We conclude that this first evidence of regression follow-
ing NST suggests a role for immunological control of
osteosarcoma by allogeneic cells. 
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